Press release BoxID: 796296 (GILUPI GmbH)
  • Hermannswerder 20a
  • 14473 Potsdam
  • Contact person
  • Claudia Chudak
  • +49 (331) 5818478-5

Change in management at GILUPI GmbH

Alexander Herrmann starts as new managing director at the medical device company

(PresseBox) (Potsdam, ) With immediate effect, Alexander Herrmann will be responsible as managing director of medical device company, located in Potsdam and Greifswald. He succeeds Klaus Lücke, who is leaving GILUPI after more than 10 years to move on to new professional challenges.

Having a master degree in Business Administration, Alexander Herrmann (43) counts many years of experience in leadership at biotechnology companies. He is supposed to speed-up the GILUPI CellCollector® marketing as well as the necessary restructuring of the company.

Mr. Herrmann commented: “The GILUPI CellCollector® is a unique and innovative product. Our target for the coming months is to enhance the GILUPI CellCollector® application by adding further molecular analytical tools, thus making the application even more valuable for our customers. Moreover, we will upscale our production capacity in Greifswald and complement our team by additional experts.

Website Promotion


GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit